Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.31 EUR
−137.34 M EUR
361.82 M EUR
291.26 M
About Amicus Therapeutics, Inc.
Sector
CEO
Bradley Lewis Campbell
Headquarters
Princeton
Website
Founded
2002
FIGI
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AM6 is 9.10 EUR — it has decreased by −1.09% in the past 24 hours. Watch AMICUS THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange AMICUS THERAPEUTICS INC stocks are traded under the ticker AM6.
AM6 stock has risen by 0.56% compared to the previous week, the month change is a −1.63% fall, over the last year AMICUS THERAPEUTICS INC has showed a −27.20% decrease.
We've gathered analysts' opinions on AMICUS THERAPEUTICS INC future price: according to them, AM6 price has a max estimate of 20.31 EUR and a min estimate of 11.60 EUR. Watch AM6 chart and read a more detailed AMICUS THERAPEUTICS INC stock forecast: see what analysts think of AMICUS THERAPEUTICS INC and suggest that you do with its stocks.
AM6 stock is 1.10% volatile and has beta coefficient of 0.14. Track AMICUS THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is AMICUS THERAPEUTICS INC there?
Today AMICUS THERAPEUTICS INC has the market capitalization of 2.74 B, it has decreased by −0.16% over the last week.
Yes, you can track AMICUS THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
AMICUS THERAPEUTICS INC is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
AM6 earnings for the last quarter are −0.02 EUR per share, whereas the estimation was 0.00 EUR resulting in a −1.79 K% surprise. The estimated earnings for the next quarter are 0.01 EUR per share. See more details about AMICUS THERAPEUTICS INC earnings.
AMICUS THERAPEUTICS INC revenue for the last quarter amounts to 127.10 M EUR, despite the estimated figure of 121.18 M EUR. In the next quarter, revenue is expected to reach 142.50 M EUR.
AM6 net income for the last quarter is −6.04 M EUR, while the quarter before that showed −14.65 M EUR of net income which accounts for 58.76% change. Track more AMICUS THERAPEUTICS INC financial stats to get the full picture.
No, AM6 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 9, 2025, the company has 517.00 employees. See our rating of the largest employees — is AMICUS THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AMICUS THERAPEUTICS INC EBITDA is 20.74 M EUR, and current EBITDA margin is −16.43%. See more stats in AMICUS THERAPEUTICS INC financial statements.
Like other stocks, AM6 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AMICUS THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AMICUS THERAPEUTICS INC technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AMICUS THERAPEUTICS INC stock shows the sell signal. See more of AMICUS THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.